Tag archive for ‘AR 101 and peanut allergy’
New Approach to SmithOnStocks Reports Starts with Aimmune Therapeutics (AIMT, $18.73)
My coverage strategy has been to identify stocks that I believed to be buys and initiate coverage with an in-depth report to be followed by updates. This is the classic Wall Street approach that was drilled into my psyche for nearly 35 years. The downside is that it takes a long time to research a […]